Skip to content

Author

Shuiling Xie

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma.

Minimal residual disease (MRD) detection is crucial for managing lymphoid malignancies. This study introduces OriMIRACLE LTM, a novel next-generation sequencing (NGS)-based B-cell receptor (BCR) and T-cell receptor (TCR) clonality assay for MRD detection. We validated the assay using cell lines and clinical samples, in...

Shuiling Xie, Changfeng Liao, Liu-Yan Xin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.